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l of ChemAbstract This study illustrates development and validation of a simple high performance liquid
chromatographic method for the simultaneous determination of metformin hydrochloride and
angiotensin-converting enzyme inhibitors (captopril, lisinopril, and enalapril) in bulk dosage form
and their application in pharmacokinetic studies. The quality resolute chromatogram was obtained
by using a Purospher Star RP-18 endcapped (250 · 4.6 mm id) column as stationary phase while
acetonitrile-water 50:50 (v/v) as mobile phase, adjusted to pH 3.0 with phosphoric acid. Efﬂuent
was monitored at a ﬂow rate of 1 mL min1 at room temperature (25 C), detector was set at
218 nm. The method was validated according to ICH guidelines. The linearity was studied over
the concentration range of 10–10,000 ng mL1 for metformin and 30–10,000 ng mL1 for captopril,
lisinopril, and enalapril, demonstrating good linearity with minimum r= 0.9964, respectively. The
developed method was successfully applied to pharmacokinetic studies of metformin, lisinopril,
captopril and enalapril.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Sufferings of people from diabetes mellitus and hypertension
are most common nowadays and these diseases have been2 2524224.
.com (F.A. Siddiqui).
Saud University.
g by Elsevier
. Production and hosting by Elsev
1.035
ui, F.A. et al., Concurrent determin
istry (2014), http://dx.doi.org/10.1the leading cause of morbidity. Generally it has been noted
that a patient suffering from diabetes also suffers from the sis-
ter disease hypertension, and the two coexists in association.
Angiotensin-converting enzymes are broadly used in order to
treat hypertension and heart failure. The inhibitors of the
angiotensin-converting enzyme may be recommended along
or in combination in combination with other drugs (Cocolas
et al., 1998). Despite the fact that ACEI (angiotensin-convert-
ing enzyme inhibitors) (Fig. 1) possess contraindications, they
are considered ﬁrst-line therapy owing to the overwhelming
beneﬁts they bring to diabetic patients (Vaughan et al., 1997;
Di Pasquale et al., 1997).ier B.V. All rights reserved.
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Figure 1 Chemical structure of all drugs.
2 F.A. Siddiqui et al.Metformin (N,N-dimethylimidodicarbonimidic diamide)
(Fig. 1), has been the crown anti-diabetic drug included in
the World Health Organization Model List of Essential Med-
icines in the year 2008. It can be rightly said that treatment of
type 2 diabetes is not complete without the administration of
metformin and it is the drug of choice particularly for obese
patients. Metformin helps in the reduction of LDL cholesterol
and triglyceride and hence may aid weight loss (Medicines,
2007). Captopril chemically known as (2S)-1-[(2S)-2-methyl-
3-sulfanylpropanoyl] pyrrolidine-2-carboxylic acid is an exten-
sively prescribed antihypertensive drug and was the ﬁrst inhib-
itor of angiotensin converting enzyme. Enalapril, an ACE
inhibitor used in the treatment of hypertension and some types
of chronic heart failure is chemically (2S)-1-[(2S)-2-{[(2S)-1-
ethoxy-1-oxo-4-phenylbutan-2-l]amino}propanoyl]pyrroli-
dine-2-carboxylic acid. The uniqueness of enalapril is that it
was the ﬁrst member of its group (ACE inhibitors) that has
two attached carboxylic acid groups. Another orally active
drug Lisinopril (N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-
L-proline) belonging to ACE inhibitors is effective in lowering
blood pressure, renovascular hypertension and congestive
heart failure. It is a lysine analog of enalaprilate (Lancaster
and Todd, 1988).
A comprehensive literature survey done in this regard re-
vealed few analytical reports for the analysis of these drugsPlease cite this article in press as: Siddiqui, F.A. et al., Concurrent determin
macokinetics. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1using HPLC alone or in combination (Europe Pharmacopoeia,
2001; Strasbourg, 2001; Amini et al., 1999; Bahmaei et al.,
1997; Hillaert and Van den Bossche, 1999; Huang et al.,
2006; Shimada et al., 1982; Tajerzadeh and Hamidi, 2001;
Anzenbacherova´ et al., 2001; States Pharmacopoeia Convention,
2006; Al-Momani, 2001; Dinc¸ et al., 2005; Wong and Charles,
1995; Sagirli and Ersoy, 2004; Rastkari et al., 2013; Sun et al.,
2010, 2013; uczak et al., 2012; Ramusovic et al., 2012; Qin
et al., 2012; Lima et al., 2009; Sun et al., 2010; Zhu et al.,
2008; Rezk et al., 2013; Li et al., 2013; Sultana et al., 2011).
None of these methods can be used for the simultaneous
estimation of these co-prescribed and co administered drugs
at the therapeutic monitoring level. There was a need to devel-
op a simultaneous LC method for above mentioned drugs.
present work describe development of a selective and sensitive
HPLC methods for the determination of these drugs in
pharmaceutical formulation and in human serum, using most
common UV detection and having proven abilities for
pharmacokinetics studies. Robustness studies were completed
to ensure continuous performance of the methods in diverse
analytical environments.2. Experimental
2.1. Apparatus and materials
Metformin hydrochloride, captopril, lisinopril and enalapril
reference standards were benevolently supplied by Sonaphy
Aventis Limited, Efroze Chemical industries (Pvt.) Ltd., Atco
Laboratories (Pvt.) Ltd. and Nabi Qasim Industries (Pvt.)
Ltd., respectively. All the tablets were purchased from local
market. Analytical grade phosphoric acid (85% pure), and
HPLC grade methanol were purchased from Merck Marker
Ltd. Water was distilled twice and was deionized by Stedec
CSW-300. Ultrasonic bath (Elmasoni E 60 H), Jenway 3240
pH meter, stability Chamber (BINDER KBF 720 (E5.2)),
Oven (Memmert D-91126) Schwabach FRG Germany and
Sartorious TE2145 analytical balance was used in this work.
Drug-free human plasma was obtained from the National
Institute of Cardiovascular Disease, Karachi, Pakistan (NIC-
VD). Caffeine was purchased from Merck.
2.2. Chromatographic condition
Shimadzu liquid chromatographic system of Shimadzu Corpo-
ration Tokyo Japan was used which consisting of Pump model
(LC-20 AT VP), Detector model (SPD-20AV), Rheodyne
manual injector ﬁtted with a 20 lL loop. Chromatographic
separation was obtained using Purospher Star RP-18 end
capped (25 cm · 4.6 mm id) analytical column. Class GC-10
software was used for data demand.
Acetonitrile–water 50:50 (v/v), pH was adjusted to 3.0 with
phosphoric acid (85%) was used as mobile phase and
acetonitrile–water 60:40 (v/v) was used as diluent. Before
delivering into the system, mobile phase was ﬁltered through
0.45lm ﬁlter and degassed using an ultrasonic bath.
Isocratic conditions were adopted using a ﬂow rate of
1.0 mL min1 at room temperature with detecting wave length
at 218 nm. This allowed the detection of all drugs with ample
sensitivity.ation of Metformin and some ACE inhibitors: Its application to Phar-
016/j.arabjc.2013.11.035
Concurrent determination of Metformin and some ACE inhibitors: Its application to Pharmacokinetics 33. Analytical procedures
3.1. Standard preparations
Stock solution of metformin 100 lg mL1 was prepared by dis-
solving 10 mg of active drug in 100 mL ﬂask and 250 lg mL1
of captopril, enalapril and lisinopril were prepared by dissolv-
ing 25 mg in 100 mL ﬂask separately. Sequential dilution of
these solutions were done to get a working solution with a con-
centration range 10–10,000 ng mL1 for metformin and 30–
10,000 ng mL1 for captopril, enalapril and lisinopril. Diluents
were used to prepare these working solutions and were
scanned to get the required data for the calibration curve.
3.2. Assay procedure for pharmaceutical formulations
10 Tablets of each drug were ground in a mortar and pestle,
and the required amount was carefully shifted to a 100 mL vol-
umetric ﬂask. The powder was dissolved in little diluent and
was mechanically shaken for 5 min, then the volume was ad-
justed to 100 mL using the same diluent. Sequential dilutions
were made to prepare solutions of different concentrations in
the working range and internal standard Caffeine was added.
Filtration of the samples was done using a 0.45-lm membrane
ﬁlter. Linear regression equations were used to calculate the
amount of metformin HCl and ACE inhibitors per tablet.
3.3. Preparation of drug serum sample
As the plasma samples were stored in the freezer at 80 C
they were allowed to thaw at room temperature before further
processing. The plasma samples were centrifuged at 3000 rpm
for 10 min. An aliquot of 1.0 mL was pipetted into a 10 mL
polypropylene test tube and 2.0 mL of acetonitrile was added.
The mixture was vortex mixed for a short while. It was then
left to stand for 5 min at room temperature. The mixture
was again centrifuged at 3000 rpm for 5 min. The supernatant
obtained was ﬁltered through a 0.45 lm ﬁlter. The worked out
serum was then mixed in a ratio of 1:1 with drug solutions and
was injected into the HPLC system.
3.4. In-vitro serum drug analysis
The availability of metformin, lisinopril, enalapril and capto-
pril from pooled human serum was determined by the de-
scribed chromatographic conditions. Blood samples of
healthy volunteers were collected. Volunteers (age ranging
from 22 to 28 years) were non-smokers and were not taking
any other medicines. Pre written consent was obtained from
all subjects. Multiple blood samples (10 mL) were collected
in evacuated glass tubes through an indwelling cannula placed
in the forearm veins. The blood was then slightly shaken and
centrifuged at 10,000 rpm for 10 min and the plasma separated
(Siddiqui et al., 2011). The obtained plasma was processed as
described above and stored at 20 C pending analysis.
3.5. In-vivo serum drug analysis
Blood samples were collected from subjects administered with
drugs, in tubes containing heparin before 0.5 h and at 0.5, 1.0,
1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5,Please cite this article in press as: Siddiqui, F.A. et al., Concurrent determin
macokinetics. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.19.5, 12, 24, 30, 35, 40, 45 and 50 h intervals of administration
of drug. Blood samples were centrifuged at 10,000 rpm for
10 min and plasma was separated, stored at 80 C until use
as our previous work (Siddiqui et al. 2013).
3.6. Preparation of internal standard
10 mg of caffeine was transferred to a 100 ml volumetric ﬂask
and some diluent was added to dissolve and then diluted up to
the mark, further dilutions were made.
4. Results and discussion
4.1. Method optimization
The objective of this work was to develop an Rp-HPLC meth-
od for separation of these four drugs in simultaneous isocratic
condition. Various hurdles were systematically countered to
get to optimum conditions.
Mobile phase being the polar part of reverse phase HPLC
system always has a profound effect on the separation of drug
molecules which are mostly polar in nature. So the selection of
mobile phase is cortically considered by chromatographers. For
this purpose different ratios of methanol, acetonitrile and water
were used to inspect the separation between metformin and
ACEI (captopril, enalapril and lisinopril). We achieved the best
separation in the mobile phase composition methanol and
water 50:50 (v/v) with pH maintained at 3.1 (±1). It was ob-
served that detector responded well at a wavelength of
218.0 nm, which was found to be the most probable isosbestic
point for all studied drugs when scanned in various solvents
including the diluent, thus it was selected as optimum wave-
length. The peak parameters such as height, asymmetry and
tailing etc were considered while maintaining ﬂow rate, baseline
drift etc. This analytical procedure does not involve the use of
internal standard as there was no extraction in simultaneous
determination of metformin and ACE inhibitors in human ser-
um and in pharmaceutical dosage forms. Individual drug solu-
tions (100 lg mL1) were injected into the sample loop of
20 lL, elution pattern and resolution parameters were studied
as a function of pH and water and organic modiﬁers ratios.
4.2. Method validation
4.2.1. Speciﬁcity and Robustness
This LCmethod under proposal is highly advantageous over the
other reported method for the concurrent determination of
Metformin and captopril, lisinopril and enalapril in human
plasma and dosage forms. A number of other ODS (octa deca
silane) columns and chromatographic systems tested conﬁrmed
negligible effect on the resolution of analytes. The best rugged-
ness and reproducibility was demonstrated by Purospher Star
RP-18 endcapped (25 cm · 4.6 mm id) column, hence it was
adopted in the subsequent analysis. The proposed system is rea-
sonably robust, straight forward, simple and involves com-
monly available UV detecting technique without any
extraction fatigues. A typical reference chromatogram, Metfor-
min and ACEIs (lisinopril, captopril, enalapril of pure standard
mixture using the described condition is shown in Fig. 2. Typical
chromatograms of Pharmaceutical formulation, all drugs in hu-
man serum and blank serum are shown in Fig. 3–5 respectively.ation of Metformin and some ACE inhibitors: Its application to Phar-
016/j.arabjc.2013.11.035
Figure 2 Typical chromatogram of metformin (1), internal
standard (2) (caffeine), lisinopril (3), enalapril (4) and captopril
(5) in reference standard.
Figure 4 Typical chromatogram of metformin (1), internal
standard (2) (caffeine), lisinopril (3), enalapril (4) and captopril
(5) in human serum.
4 F.A. Siddiqui et al.4.2.2. Linearity and range
For studying linearity standard solutions were prepared by
serially diluting stock solution at ﬁve concentration level for
standard reference and at seven concentration level in human
serum in the range of 10–10,000 and 30–10,000 ng mL1 for
metformin and captopril, lisinopril, and enalapril, respectively
which determined the linearity of the method (n= 3). Plotting
the mean peak areas of metformin and captopril, lisinopril,
and enalapril as a function of drug concentration gave the
least-square regression calibration curves. The linearity and
regression calibration curves equation are represented in
Tables 1 and 2, respectively.
4.2.3. Accuracy and precision
The accuracy of an analytical method is deﬁned as the similar-
ity of the results obtained by the analytical method to the trueFigure 3 Typical chromatogram of metformin (1), internal
standard (2) (caffeine), lisinopril (3), enalapril (4) and captopril
(5) in pharmaceutical formulation.
Please cite this article in press as: Siddiqui, F.A. et al., Concurrent determin
macokinetics. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1value and precision is the degree of that similarity (Guideline,
2005; Chow et al., 2002). Repeatability and reproducibility of
the method was performed as intra-day and inter-day accuracy
and precision in pharmaceutical dosage forms by injecting nine
replicates of three concentrations (80, 100 and 120%) into the
system. Coefﬁcient of variance (CV) and percentage recovery
of each drug were also evaluated as shown in Table 3.4.2.4. Recovery studies
Recovery studies were performed to check the interference of
formulation additives. This was done by adding a known
amount of pure drug to already analyzed samples of commer-
cial dosage forms. For percent analytical recovery values the
following equation was used
%Recovery ¼ ½ðCv CuÞ=Ca  100
where Cv was the total drug concentration measured after
standard addition, Cu, drug concentration in the formulationFigure 5 Typical chromatogram of blank human serum.
ation of Metformin and some ACE inhibitors: Its application to Phar-
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Table 1 Statistical regression analysis of proposed method.
Lisinopril Enalapri Captopril Metformin
Linearity 30–10,000 30–10,000 30–10,000 10–10,000
ng/ml ng/ml ng/ml ng/ml
Slope 37.99 2.8715 29.22 69.22
Intercept 199.66 165.59 102.37 111.97
LOD 3.26 1.14 1.69 0.98
LOQ 9.26 6.17 8.22 2.22
R 0.9964 0.997 0.9974 0.9986
Table 2 Linearity accuracy and precision of proposed method.
Injected conc. ng mL1 Reference sample In serum
Recovered conc. ng mL1 % Recovery %RSD n= 6 Recovered conc. ng mL1 % Recovery % RSD n= 6
Lisinopril
30 29.66 98.86667 1.45 29.3 97.66667 2.24
100 99.41 99.41 1.17 98.33 98.33 1.69
500 501.22 100.244 1.34 492.5 98.5 1.77
1000 998.7 99.87 1.29 988.66 98.866 1.05
2000 2012.6 100.63 1.77 1978.5 98.925 1.35
5000 5044.9 100.898 1.43 4926.5 98.53 0.94
10,000 1012.4 10.124 1.69 9876.5 98.765 1.06
Enalapril 2.09
30 30.11 100.3667 1.98 29.04 96.8 2.34
100 98.67 98.67 2.26 99.33 99.33 1.66
500 500.87 100.174 1.44 502.2 100.44 1.79
1000 989.4 98.94 1.69 993.4 99.34 1.24
2000 2014.5 100.725 0.88 1976.4 98.82 1.56
5000 5012.8 100.256 1.64 5012.8 100.256 1.38
10,000 9982.8 99.828 1.35 1027.6 10.276 1.97
Captopril
30 29.14 97.13333 2.09 29.14 97.13333 1.87
100 98.37 98.37 1.87 101.22 101.22 1.23
500 497.2 99.44 1.3 492.5 98.5 1.38
1000 988.6 98.86 1.46 976.5 97.65 1.45
2000 1994.4 99.72 1.29 1941.5 97.075 1.22
5000 4967.5 99.35 1.33 5032.5 100.65 1.72
10,000 9876.5 98.765 0.77 1056.8 10.568 1.69
Metformin
10 9.82 98.2 2.29 9.76 97.6 2.27
50 49.37 98.74 2.61 48.69 97.38 2.33
500 496.7 99.34 1.74 488.6 97.72 1.25
1000 992.64 99.264 1.22 1055.2 105.52 1.61
2000 1987.5 99.375 0.88 1974.2 98.71 1.11
5000 5004.5 100.09 1.09 5012.8 100.256 1.38
10,000 10121.5 101.215 1.22 10021.9 100.219 1.43
Concurrent determination of Metformin and some ACE inhibitors: Its application to Pharmacokinetics 5and Ca, drug concentration added to formulation. A sepa-
rate analysis for all the drugs was performed to
test the developed method’s precision and accuracy. All
the results were found ranging from 98.2–101.6%.
Results proved good recovery of the newly developed
method.
4.2.5. Limit of detection (LOD) and limit of quantitation
(LOQ)
The criterion for the calculation of limits of detection (LOD)
and quantitation (LOQ) was the use of empirical formula i.e,
3.3(r/s) and 10(r/s), respectively, where r is the standard devi-
ation of the peak area (for six replicates) for the sample and s isPlease cite this article in press as: Siddiqui, F.A. et al., Concurrent determin
macokinetics. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1the slope obtained from calibration curve equation (Green,
1996; Guideline, 1996). Using the parameters mentioned
above, LOD was estimated to be 3.26, 1.14, 1.69 and
0.98 ng mL1 while LOQ was 9.26, 6.17, 8.22 and
2.22 ng mL1 for lisinopril, enalapril, captopril and metfor-
min, respectively.
The uniformity of the system operation throughout the
analysis was developed by initially equilibrating the column
with mobile phase prior to injection of the sample into the
Chromatographic system. Theoretical plates, tailing factor,
resolution and repeatability were checked before starting ana-
lytical work every day. All the factors were found satisfactory
and were as per (ICH, 2003) guidelines.ation of Metformin and some ACE inhibitors: Its application to Phar-
016/j.arabjc.2013.11.035
Figure 6 Mean plasma concentration-time proﬁle after oral
administration of 20 mg of lisinopril.
Figure 7 Mean plasma concentration-time proﬁle after oral
administration of 10 mg of enalapril.
Table 3 Recovery studies of proposed method.
Concentrations (%) CV (n= 6) Recovery (%)
Day 1 Day 2 Day 3
Metformin
80 0.64 1.24 1.04 99.66
100 1.22 1.44 0.97 100.25
120 0.94 0.39 1.22 98.79
Captopril
80 0.87 1.09 1.39 99.47
100 0.96 0.38 1.04 101.25
120 29 0.88 0.77 100.39
Enalapril
80 0.66 0.79 0.79 100.76
100 1.34 0.52 0.82 99.87
120 0.47 0.96 1.06 100.81
Lisinopril
80 0.99 0.63 0.49 99.38
100 1.23 0.57 1.22 101.22
120 0.84 1.06 1.34 100.38
6 F.A. Siddiqui et al.4.3. Applicability
4.3.1. Application to human serum (in vitro study)
The applicability of the method in human serum was checked
by spiking serum sample with metformin and captopril, lisino-
pril, and enalapril simultaneously. The validated method was
effectively applied to an in-vitro study in human plasma sam-
ples for reference and test formulations of metformin (500 mg),
captopril 25 mg, lisinopril 20 mg, and enalapril 10 mg tablet
formulation. Application of proposed method was conducted
in the perspective of human serum, for this purpose at different
concentration levels of metformin, captopril, isinopril, and
enalapril were spiked with serum samples and determined in
triplicate. The prepared concentrations were analogous to
the intermediate concentration level of the calibration points.
The sample was prepared by adding 4 mL of the drug solution
(containing metformin (10 lg mL1) and captopril, lisinopril,
and enalapril (100 lg mL1) to 4 mL of drug-free human ser-
um. This spiked serum was made up to 10 mL with diluent
and injected into the chromatograph. Further dilutions were
made when and where was require. No interference was ob-
served in the analysis as shown in Figs. 4 and 5. The obtained
recoveries and %RSD are illustrated in Table 2. Statistical
analysis showed that no considerable differences exist among
the mean recoveries of all the drugs in serum samples.
4.3.2. Pharmacokinetic application (in-vivo study)
The method was applied to study the pharmacokinetic proﬁle
of drugs after oral administration of metformin (500 mg), cap-
topril 25 mg, lisinopril 20 mg, and enalapril 10 mg in 24
healthy Pakistani male volunteers with a mean age of
(22.5 ± 1.22 years and a mean body mass index (BMI) of
21.2 ± 2.12. Prior to analysis, the volunteers were on fast since
overnight and fasted for 4 h after the dosing as well. Venous
blood samples (8 ml) were collected 0.5 h before dosing and
at 00.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5,
7.0, 7.5, 8.0, 8.5, 9.5, 12, 24, 30, 35, 40, 45 and 50 hrs of interval
following administration.Please cite this article in press as: Siddiqui, F.A. et al., Concurrent determin
macokinetics. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1The blood samples were treated as mentioned in experimen-
tal section. The pharmacokinetic parameters from the plasma
concentration-time proﬁle for each volunteer were evaluated.
Before pharmacokinetics studies all volunteers were informed
of the aim of the study, written consent was taken from all vol-
unteers and Ethics committee approved the study protocol.
The study was performed strictly in accordance Interna-
tional Conference on Harmonization and USFDA (Guidance
for Industry, 2001). All volunteers were checked up by general
physician and found satisfactory health for conducting phar-
macokinetics studies. All subjects were negative for HIV,
HBSAg and HCV tests. All subjects were orally administered
a single dose of test and reference drug with 240 ml of water.
Drinking water was not allowed and supine position was re-
stricted 2 h post dose. Standardized meals were provided as
per requirement. The guidelines laid down by International
Conference on Harmonization and USFDA (Guidance for
Industry, 2001) were ﬁrmly followed in this study.
The peak plasma level of captopril was attained at almost
0.5 hrs after the administration and was found to be in good
conformity with the values reported by Jankowski et al.
(1995). The Plasma levels of Lisinopril achieved from healthy
volunteers after the administration of a single dose was also
found to be in good agreement with the value reported by
Feng et al. (2012). In the same way plasma concentration time
proﬁle of enalapril and plasma concentration of metformin
were also in good agreement with the reported values of Fodaation of Metformin and some ACE inhibitors: Its application to Phar-
016/j.arabjc.2013.11.035
Figure 8 Mean plasma concentration-time proﬁle after oral
administration of 25 mg of captopril.
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Figure 9 Mean plasma concentration-time proﬁle after oral
administration of 500 mg of metformin.
Table 4 Stability studies using proposed method.
Month Lisinopril Enalapri Captopril Metformin
%Recovery RSD% %Recovery RSD% %Recovery RSD% %Recovery RSD%
40 C/75% R.H
1st 99.98 0.66 100.94 0.39 99.96 1.02 101.29 0.49
2nd 99.46 0.94 100.67 0.89 99.39 0.86 100.98 1.34
3rd 99.06 0.88 100.22 1.02 99.09 0.71 100.76 1.06
6th 98.25 0.97 99.97 1.22 98.76 0.93 100.33 0.92
30 C/65% R.H
1st 100.56 0.49 100.39 0.91 99.41 0.69 99.69 0.99
2nd 100.29 0.59 100.29 0.98 99.22 0.82 99.32 1.28
3rd 100.06 0.38 100.06 0.52 99.12 0.86 99.14 0.58
6th 99.89 0.92 99.76 0.64 98.85 0.84 98.69 1.08
Concurrent determination of Metformin and some ACE inhibitors: Its application to Pharmacokinetics 7et al. (2010) and Mistri et al. (2007), Siddiqui et al. (2013)
respectively. The mean plasma concentration-time proﬁle of
four drugs in volunteers is represented in Figs. 6–9.
4.4. Stability studies
The stability studies were performed and six lots of commer-
cially available drugs were obtained. Accelerated and long
term ambient condition studies were carried out as described
by ICH (2003). It was found that the commercially available
lots are stable up to the six month. Two sets of studies were
done one at accelerated conditions and the other one at long
term ambient conditions as described by ICH (2003). Both
the studies showed that all the drugs are stable in the men-
tioned conditions. % Recoveries of all the drugs obtained were
almost 100%, Table 4.
5. Conclusion
The proposed HPLC method described in this paper provides
a simple, universal, convenient and reproducible approach for
the simultaneous identiﬁcation and quantiﬁcation of metfor-
min, captopril, lisinopril and enalapril in biological ﬂuids
with good separation and resolution. In addition, this method
has the ability to be applied to pharmacokinetic studies inPlease cite this article in press as: Siddiqui, F.A. et al., Concurrent determin
macokinetics. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1human volunteers and Analytical results are accurate and
precise with good recovery. This assay method was also suc-
cessfully applied in raw materials and pharmaceutical formu-
lations. Linearity, accuracy, precision, limit of detection and
quantiﬁcation, speciﬁcity were established. Hence this method
is beneﬁcial for quality control laboratories as well as bio-
analytical laboratories. This method can not only be used
to study dissolution and pharmacokinetics but also therapeu-
tic monitoring of the mentioned drugs can be studied in dia-
betic and hypertension patients having simultaneous drug
prescription.References
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